Motolimod NEW
| Price | $31 | $73 | $118 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Motolimod | CAS No.: 926927-61-9 |
| Purity: 99.27% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Motolimod |
| Description | Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7. |
| Cell Research | PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell-mediated cytotoxicity is assessed by Calcein-AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells. |
| Kinase Assay | The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out. |
| In vitro | Motolimodinduces the production of both TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs. In mDCs and monocytes, Motolimodspecifically induces the production of IL-12 and TNFα via NF-κB activation. Motolimodalso induces IFNγ production from NK cells, enhances the lytic function of NK cells and augments ADCC. |
| In vivo | In ovarian cancer mouse model, TX-2337 augments the effect of pegylated liposomal doxorubicin (PLD). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 12 mg/mL (26.2 mM) DMSO : 51 mg/mL (111.2 mM) |
| Keywords | inhibit | VTX378 | VTX 2337 | VTX2337 | Inhibitor | Toll-like Receptor (TLR) | VTX 378 | Motolimod |
| Inhibitors Related | Polyinosinic-polycytidylic acid sodium | CU-CPD107 | Imiquimod hydrochloride | Hydroxychloroquine | Chloroquine phosphate | Hydroxychloroquine sulfate | Chloranil | Chloroquine | CU-115 | Imiquimod | TLR3-IN-1 | Resiquimod |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY